Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | IL6ST | P40189 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676221 | 1.00 | PPARA (0.38) | PPARAGCKCA1CA2CA4 | |
| SCHEMBL2676265 | 1.00 | PPARA (0.38) | PPARAGCKCA1CA2CA4 | |
| SCHEMBL1931231 | 0.89 | GCK (0.42) | PPARAGCKCCR5 | |
| SCHEMBL2647404 | 0.89 | GCK (0.42) | PPARAGCKCCR5 | |
| SCHEMBL1931229 | 0.89 | GCK (0.42) | PPARAGCKCCR5 | |
| SCHEMBL2647402 | 0.89 | GCK (0.42) | PPARAGCKCCR5 | |
| SCHEMBL2656401 | 0.89 | GCK (0.42) | PPARAGCKCCR5 | |
| SCHEMBL2647802 | 0.89 | GCK (0.42) | PPARAGCKCCR5 | |
| SCHEMBL10049895 | 0.89 | PPARA (0.40) | PPARAIL6STIDH1AGTR2NAAA | |
| SCHEMBL2659612 | 0.88 | GCK (0.47) | PPARAGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116535-B1 | GLUCOKINASE-ACTIVATING SUBSTANCE | KYORIN SEIYAKU KK (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-8173649-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | PPARA 2242/4885GCK 1/4885CA1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.